Aurinia Pharmaceuticals Inc (NAS:AUPH)
$ 5.36 -0.06 (-1.11%) Market Cap: 766.59 Mil Enterprise Value: 543.79 Mil PE Ratio: 0 PB Ratio: 2.14 GF Score: 72/100

Q3 2022 Aurinia Pharmaceuticals Inc Earnings Call Transcript

Nov 03, 2022 / 12:30PM GMT
Release Date Price: $5.18 (-31.93%)
Operator

Greetings, and welcome to the Aurinia Pharmaceuticals Inc Third Quarter 2022 Earnings Call. (Operator Instructions) As a reminder, this conference is being recorded.

I would now like to turn the conference over to your host, [John Wolford], Investor Relations for Aurinia Pharmaceuticals. You may begin.

Unidentified Company Representative

Thank you, Melissa, and thank you all for joining today's call and webcast to discuss Aurinia's third quarter 2022 results. Joining me this morning to lead the call are Peter Greenleaf, President and Chief Executive Officer; and Joe Miller, Chief Financial Officer.

This morning, Aurinia issued a press release announcing its financial results and recent operational highlights, and filed its quarterly report on Form 10-Q. For more information, please refer to Aurinia's filings with the U.S. Securities and Exchange Commission, which are also available on Aurinia's website at auriniapharma.com.

During this call, Aurinia -- we may make forward-looking statements based on current expectations. These forward

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot